Cargando…

Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo

OBJECTIVES: Antitumour necrosis factor (TNF) therapy has revolutionised treatment of several chronic inflammatory diseases, including spondyloarthritis (SpA). However, TNF inhibitors (TNFi) are not effective in all patients and the biological basis for treatment failure remains unknown. We have anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menegatti, Silvia, Guillemot, Vincent, Latis, Eleonora, Yahia-Cherbal, Hanane, Mittermüller, Daniela, Rouilly, Vincent, Mascia, Elena, Rosine, Nicolas, Koturan, Surya, Millot, Gael A, Leloup, Claire, Duffy, Darragh, Gleizes, Aude, Hacein-Bey-Abina, Salima, Sellam, Jérémie, Berenbaum, Francis, Miceli-Richard, Corinne, Dougados, Maxime, Bianchi, Elisabetta, Rogge, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958106/ https://www.ncbi.nlm.nih.gov/pubmed/33268443 http://dx.doi.org/10.1136/annrheumdis-2020-218304

Ejemplares similares

Characterization of Blood Mucosal‐Associated Invariant T Cells in Patients With Axial Spondyloarthritis and of Resident Mucosal‐Associated Invariant T Cells From the Axial Entheses of Non‐Axial Spondyloarthritis Control Patients
por: Rosine, Nicolas, et al.
Publicado: (2022)

Characterisation of gut microbiota composition in patients with axial spondyloarthritis and its modulation by TNF inhibitor treatment
por: Vallier, Marie, et al.
Publicado: (2023)

Factors associated with a bad functional prognosis in early inflammatory back pain: results from the DESIR cohort
por: Lukas, C, et al.
Publicado: (2016)

Expansion of Interleukin‐22– and Granulocyte–Macrophage Colony‐Stimulating Factor–Expressing, but Not Interleukin‐17A–Expressing, Group 3 Innate Lymphoid Cells in the Inflamed Joints of Patients With Spondyloarthritis
por: Blijdorp, Iris C. J., et al.
Publicado: (2019)

Responsiveness of a simple RAPID-3-like index compared to disease-specific BASDAI and ASDAS indices in patients with axial spondyloarthritis
por: Castrejón, Isabel, et al.
Publicado: (2016)

MRI for diagnosis of axial spondyloarthritis: major advance with critical limitations ‘Not everything that glisters is gold (standard)’
por: Lukas, Cédric, et al.
Publicado: (2018)

Clinical profile and treatment utilisation based on HLA-B*27 status in axial spondyloarthritis: results from ASAS-PerSpA study
por: Chaudhary, Haseeb, et al.
Publicado: (2023)

Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohort
por: Harvard, Stephanie, et al.
Publicado: (2016)

Gene therapy for severe combined immunodeficiencies and beyond
por: Fischer, Alain, et al.
Publicado: (2019)

Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis
por: López-Medina, Clementina, et al.
Publicado: (2019)

Evaluation of long-term TNFi effectiveness after a first switch in early axial spondyloarthritis considering time-varying prescription bias: an inverse-probability weighting analysis of the DESIR cohort
por: Pons, Marion, et al.
Publicado: (2022)

Does gender influence outcome measures similarly in patients with spondyloarthritis? Results from the ASAS-perSpA study
por: Benavent, Diego, et al.
Publicado: (2022)

Inflammation of the Sacroiliac Joints and Spine and Structural Changes on Magnetic Resonance Imaging in Axial Spondyloarthritis: Five‐Year Data From the DESIR Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
por: Braun, Jürgen, et al.
Publicado: (2022)

Imaging Outcomes for Axial Spondyloarthritis and Sensitivity to Change: A Five‐Year Analysis of the DESIR Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2022)

Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study
por: Arevalo Salaet, Marta, et al.
Publicado: (2022)

Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis
por: Ramiro, Sofia, et al.
Publicado: (2015)

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study
por: Webers, Casper, et al.
Publicado: (2018)

Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France
por: Dougados, Maxime, et al.
Publicado: (2022)

Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)
por: Dougados, Maxime, et al.
Publicado: (2023)

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
por: Kiltz, Uta, et al.
Publicado: (2020)

5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort
por: Madari, Queeny, et al.
Publicado: (2020)

Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)
por: Deodhar, Atul A., et al.
Publicado: (2016)

Supervised Group Exercise in Axial Spondyloarthritis: Patients' Satisfaction and Perspective on Evidence‐Based Enhancements
por: Hilberdink, Bas, et al.
Publicado: (2020)

Can power Doppler ultrasound of the entheses help in classifying recent axial spondyloarthritis? Data from the DESIR cohort
por: Poulain, Cecile, et al.
Publicado: (2018)

Rate and Predisposing Factors for Sacroiliac Joint Radiographic Progression After a Two‐Year Follow‐up Period in Recent‐Onset Spondyloarthritis
por: Dougados, Maxime, et al.
Publicado: (2016)

Evaluation of the performances of ‘typical’ imaging abnormalities of axial spondyloarthritis: results of the cross-sectional ILOS-DESIR study
por: Molto, Anna, et al.
Publicado: (2019)

Prevalence of degenerative changes and overlap with spondyloarthritis-associated lesions in the spine of patients from the DESIR cohort
por: de Bruin, Freek, et al.
Publicado: (2018)

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Spinal Radiographic Progression in Early Axial Spondyloarthritis: Five‐Year Results From the DESIR Cohort
por: Ramiro, Sofia, et al.
Publicado: (2019)

A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
por: Sieper, J, et al.
Publicado: (2015)

Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life
por: Imkamp, Maike, et al.
Publicado: (2018)

Expression analysis of HLA-E and NKG2A and NKG2C receptors points at a role for natural killer function in ankylosing spondylitis
por: Cauli, Alberto, et al.
Publicado: (2018)

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
por: Abbara, Salam, et al.
Publicado: (2019)

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
por: Dougados, Maxime, et al.
Publicado: (2020)

Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10(®) to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies
por: Berger, Anne Emmanuelle, et al.
Publicado: (2022)

Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study
por: Kishimoto, Mitsumasa, et al.
Publicado: (2021)

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial
por: Molto, Anna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ohikf8aktfiqnb8sa4emanq1t7